Silvio Inzucchi, MD, discusses his presentation on the role of diabetes medications, including SGLT2 inhibitors and GLP-1 RAs, in stroke prevention from TMIOA's 5th Heart in Diabetes conference.
SGLT2 inhibitors have made major headlines in recent years with revelations of their cardiorenal protective benefits, but endocrinologists and cardiologists alike have pointed out use agents within the class does not provide a reduction in risk of stroke.
The topic of the role of diabetes medications in stroke prevention was the focus of a discussion led by Silvio Inzucchi, MD, professor of medicine at the Yale School of Medicine, at The Metabolic Institute of America’s (TMIOA) 2021 Heart in Diabetes sessions in New York, NY. During his discussion, Inzucchi provided an overview of the effects of newer diabetes medications on stroke but also touched upon potential reductions observed with more entrenched staples of diabetes management.
After his presentation at Heart in Diabetes, our sister publication HCPLive sat down with Inzucchi for more insight into his presentation and the role of diabetes medications in stroke prevention.